Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market closed
8 216,78 pts
-1.62%


Last updated : 17/11/2026 - 17h35
🏠 Home   ➤    Stock news

Valneva shares fall 15% over three months and drop back below their MM50

The Lyon-based vaccine maker is not benefiting from the rebound that began early in the month and is giving back ground in a Paris market clearly tilted to the downside. The session erases part of the progress made over the past few weeks, while the company's next publication is approaching.


Valneva shares fall 15% over three months and drop back below their MM50

A decline that brings it to the bottom of its index, in a retreating SBF 120

Valneva shares lost 2.15% to €2.55 at the close, while the SBF 120 fell 1.56% and the CAC 40 fell 1.6%. The stock ranks near the bottom of its index, without being among the largest declines of the session.

The move is part of a broadly negative day: the DAX fell 1.86% and the Dow Jones 1.46%, while the VIX rose 11.7% to 25.59.

Sanofi, another stock in the sector, fell 2.02% but retains a gain of roughly 20% over one month, whereas Valneva shows only 1.07% over the same period. Over one week, the stock is down 1.62%, a moderate decline that contrasts with the 15.13% drop over three months.

MM50 lost again at €2.62, MM20 still within reach

On the moving averages, the price of €2.55 has dropped back below the MM50 (€2.62), a gap of 2.82%, after having recovered it during the rebound of recent sessions. It nevertheless remains slightly above the MM20 (€2.52), a gap of 1.03%: this is the level the stock is now testing.

The MM200 stands at €2.84, 10.35% above the current price, which measures the distance still to be covered to regain a long-term trend. Support is at €2.33 and resistance at €2.68. Valneva will publish its results for the first nine months of 2026 on November 24.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Pharmacie, vaccins et santé animale


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 65,8 millions d'euros
  • Quarterly revenue: 65,8 millions d'euros
  • Revenue growth: -32,6 %
  • EBITDA: -39,8 millions d'euros
  • EBITDA margin: -60,4 %
  • Net income: -63,3 millions d'euros
Guidance from the release
  • Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
  • Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
  • Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
  • Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
  • Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
  • Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
  • Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
  • Expected revenue: 147,5 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours